intravenous erythropoietin for treatment of indirect traumatic optic neuropathy (TON) and compared the outcomes of such treatment with no specific intervention. Mean best-corrected visual acuity (BCVA) significantly (P=0.028) improved from 1.82 logMAR at baseline to 0.94 logMAR at final follow-up in the EPO group, whereas the observation group showed insignificant (P=0.28) visual improvement from 2.55 logMAR to 2.32 logMAR. Li et al determined the effect of intravitreal erythropoietin in 5 eyes with severe, chronic diabetic macular edema unresponsive to prior multi-modal treatment. They reported that visual acuity improved by 3 lines or more in 3 eyes and by 1 line in 2 eyes. Visual improvement occurred within a week after initial intravitreal EPO injection and was maintained up to 18 weeks. Modarres et al reported the results of intravitreal injection of erythropoietin in eyes with non-arteritic anterior ischemic optic neuropathy. After the injections, 64.5% and 54.8% of eyes experienced 3 or more lines of improvement in visual acuity at 3 months and at final follow-up, respectively. Their results were distinctly superior to the natural course of the disease (39.5% rate of improvement of 3 lines or more after 3 months according to the Ischemic Optic Neuropathy Decompression Trial).
Neuroprotection is an evolving strategy for limiting or possibly reversing neuronal/ axonal injury due to a variety of insults. This concept may be used as a therapeutic option in glaucoma, vascular occlusions, or retinal degenerative disorders. Further studies are required to elucidate the potential benefits of erythropoietin in different ocular conditions.
